Literature DB >> 10488073

Development of substituted Benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel.

F Becq1, Y Mettey, M A Gray, L J Galietta, R L Dormer, M Merten, T Métayé, V Chappe, C Marvingt-Mounir, O Zegarra-Moran, R Tarran, L Bulteau, R Dérand, M M Pereira, M A McPherson, C Rogier, M Joffre, B E Argent, D Sarrouilhe, W Kammouni, C Figarella, B Verrier, M Gola, J M Vierfond.   

Abstract

Chloride channels play an important role in the physiology and pathophysiology of epithelia, but their pharmacology is still poorly developed. We have chemically synthesized a series of substituted benzo[c]quinolizinium (MPB) compounds. Among them, 6-hydroxy-7-chlorobenzo[c]quinolizinium (MPB-27) and 6-hydroxy-10-chlorobenzo[c]quinolizinium (MPB-07), which we show to be potent and selective activators of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. We examined the effect of MPB compounds on the activity of CFTR channels in a variety of established epithelial and nonepithelial cell systems. Using the iodide efflux technique, we show that MPB compounds activate CFTR chloride channels in Chinese hamster ovary (CHO) cells stably expressing CFTR but not in CHO cells lacking CFTR. Single and whole cell patch clamp recordings from CHO cells confirm that CFTR is the only channel activated by the drugs. Ussing chamber experiments reveal that the apical addition of MPB to human nasal epithelial cells produces a large increase of the short circuit current. This current can be totally inhibited by glibenclamide. Whole cell experiments performed on native respiratory cells isolated from wild type and CF null mice also show that MPB compounds specifically activate CFTR channels. The activation of CFTR by MPB compounds was glibenclamide-sensitive and 4, 4'-diisothiocyanostilbene-2,2'-disulfonic acid-insensitive. In the human tracheal gland cell line MM39, MPB drugs activate CFTR channels and stimulate the secretion of the antibacterial secretory leukoproteinase inhibitor. In submandibular acinar cells, MPB compounds slightly stimulate CFTR-mediated submandibular mucin secretion without changing intracellular cAMP and ATP levels. Similarly, in CHO cells MPB compounds have no effect on the intracellular levels of cAMP and ATP or on the activity of various protein phosphatases (PP1, PP2A, PP2C, or alkaline phosphatase). Our results provide evidence that substituted benzo[c]quinolizinium compounds are a novel family of activators of CFTR and of CFTR-mediated protein secretion and therefore represent a new tool to study CFTR-mediated chloride and secretory functions in epithelial tissues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488073     DOI: 10.1074/jbc.274.39.27415

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Designer pharmacotherapy for the treatment of cystic fibrosis: commentary on Zegarra-Moran et al.

Authors:  M A Gray
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

2.  Activation mechanisms for the cystic fibrosis transmembrane conductance regulator protein involve direct binding of cAMP.

Authors:  Malcolm M C Pereira; Jody Parker; Fiona L L Stratford; Margaret McPherson; Robert L Dormer
Journal:  Biochem J       Date:  2007-07-01       Impact factor: 3.857

3.  Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis.

Authors:  R L Dormer; C M Harris; Z Clark; M M C Pereira; I J M Doull; C Norez; F Becq; M A McPherson
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

4.  Enhancing the Potency of F508del Correction: A Multi-Layer Combinational Approach to Drug Discovery for Cystic Fibrosis.

Authors:  Emily F Kirby; Ashley S Heard; X Robert Wang
Journal:  J Pharmacol Clin Toxicol       Date:  2013-08-28

5.  Transient receptor potential melastatin 4 inhibitor 9-phenanthrol abolishes arrhythmias induced by hypoxia and re-oxygenation in mouse ventricle.

Authors:  Christophe Simard; Laurent Sallé; René Rouet; Romain Guinamard
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 6.  CFTR pharmacology.

Authors:  Olga Zegarra-Moran; Luis J V Galietta
Journal:  Cell Mol Life Sci       Date:  2016-10-04       Impact factor: 9.261

7.  Phenanthrolines--a new class of CFTR chloride channel openers.

Authors:  M Duszyk; L MacVinish; A W Cuthbert
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

8.  Characterization of a 7,8-benzoflavone double effect on CFTR Cl(-) channel activity.

Authors:  Loretta Ferrera; Chiara Pincin; Oscar Moran
Journal:  J Membr Biol       Date:  2007-09-18       Impact factor: 1.843

9.  Direct effects of 9-anthracene compounds on cystic fibrosis transmembrane conductance regulator gating.

Authors:  Tomohiko Ai; Silvia G Bompadre; Yoshiro Sohma; Xiaohui Wang; Min Li; Tzyh-Chang Hwang
Journal:  Pflugers Arch       Date:  2004-10       Impact factor: 3.657

10.  9-phenanthrol inhibits human TRPM4 but not TRPM5 cationic channels.

Authors:  T Grand; M Demion; C Norez; Y Mettey; P Launay; F Becq; P Bois; R Guinamard
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.